Anti-NOTCH3 antibodies

US10745476B2 · kind B2 · utility

Assignee

• AVEO Pharmaceuticals, Inc. · US

Inventors

• Heidi Okamura · Brookline, US
• Sandra Abbott · Boston, US
• Alisa C. Bell · Bedford, US
• Kelly Kreuter · Arvada, US
• Ronan O'Hagan · Waltham, US
• Samantha Perino · Watertown, US
• Hamid Tissire · Abington, US
• William M. Winston, Jr. · Marlborough, US
• Jeno Gyuris · Lincoln, US

Key dates

• Filing date: Jan 8, 2018
• Grant date: Aug 18, 2020
• Expiry date: May 1, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N5/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.